Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-15 8:15 pm Unchanged |
2025-03-31 | 13G | NeuroPace, Inc. NPCE |
ORBIMED ADVISORS LLC | 3,406,335 10.500% |
0 (Unchanged) |
Filing History |
| 2025-05-15 8:13 pm Unchanged |
2025-03-31 | 13G | InspireMD, Inc. NSPR |
ORBIMED ADVISORS LLC | 2,133,405 7.200% |
0 (Unchanged) |
Filing History |
| 2025-05-15 8:09 pm Purchase |
2025-03-31 | 13G | C4 Therapeutics, Inc. CCCC |
ORBIMED ADVISORS LLC | 4,655,600 6.600% |
4,655,600 (New Position) |
Filing History |
| 2025-05-15 6:46 pm Purchase |
2025-03-31 | 13G | Whitehawk Therapeutics Inc WHWK |
ORBIMED ADVISORS LLC | 4,166,000 8.900% |
4,166,000 (New Position) |
Filing History |
| 2025-05-15 6:41 pm Sale |
2025-03-31 | 13G | Verastem, Inc. VSTM |
ORBIMED ADVISORS LLC | 2,862,448 5.600% |
-1,286,414 (-31.01%) |
Filing History |
| 2025-05-14 8:49 pm Unchanged |
2025-05-12 | 13D | Corvus Pharmaceuticals, Inc. CRVS |
ORBIMED ADVISORS LLC | 9,785,423 12.200% |
0 (Unchanged) |
Filing History |
| 2025-05-12 7:13 pm Purchase |
2025-05-09 | 13D | Edgewise Therapeutics, Inc. EWTX |
ORBIMED ADVISORS LLC | 15,252,867 14.500% |
496,771 (+3.37%) |
Filing History |
| 2025-05-01 9:20 pm Purchase |
2025-04-29 | 13D | Corvus Pharmaceuticals, Inc. CRVS |
ORBIMED ADVISORS LLC | 9,785,423 13.800% |
2,841,769 (+40.93%) |
Filing History |
| 2025-04-25 7:48 pm Sale |
2025-04-22 | 13D | Passage Bio, Inc. PASG |
ORBIMED ADVISORS LLC | 6,650,000 10.700% |
-754,869 (-10.19%) |
Filing History |
| 2025-04-14 7:09 pm Sale |
2025-04-10 | 13D | Xtant Medical Holdings, Inc. XTNT |
ORBIMED ADVISORS LLC | 0 0.000% |
-73,114,592 (Position Closed) |
Filing History |
| 2025-04-11 7:21 pm Sale |
2024-04-09 | 13D | Compass Therapeutics, Inc. CMPX |
ORBIMED ADVISORS LLC | 15,219,994 11.000% |
-3,571,428 (-19.01%) |
Filing History |
| 2025-03-12 7:57 pm Sale |
2025-03-10 | 13D | Disc Medicine, Inc. IRON |
ORBIMED ADVISORS LLC | 1,556,369 4.500% |
-229,202 (-12.84%) |
Filing History |
| 2025-02-14 4:35 pm Purchase |
2024-12-31 | 13G | ADC Therapeutics SA ADCT |
ORBIMED ADVISORS LLC | 3,437,813 3.600% |
3,437,813 (New Position) |
Filing History |
| 2025-02-14 4:32 pm Purchase |
2024-12-31 | 13G | RAPT Therapeutics, Inc. RAPT |
ORBIMED ADVISORS LLC | 13,135,260 9.900% |
13,135,260 (New Position) |
Filing History |
| 2025-02-14 4:30 pm Purchase |
2024-12-31 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP |
ORBIMED ADVISORS LLC | 718,200 5.900% |
129,000 (+21.89%) |
Filing History |
| 2025-02-14 4:22 pm Purchase |
2024-12-31 | 13G | Forte Biosciences, Inc. FBRX |
ORBIMED ADVISORS LLC | 510,000 8.000% |
510,000 (New Position) |
Filing History |
| 2025-02-13 4:47 pm Purchase |
2025-02-10 | 13D | Sionna Therapeutics, Inc. SION |
ORBIMED ADVISORS LLC | 3,704,959 8.400% |
3,704,959 (New Position) |
Filing History |
| 2025-01-29 6:42 pm Purchase |
2024-12-31 | 13D | Traws Pharma, Inc. TRAW |
ORBIMED ADVISORS LLC | 760,824 19.900% |
155,293 (+25.65%) |
Filing History |
| 2024-12-26 4:31 pm Sale |
2024-12-20 | 13D | Passage Bio, Inc. PASG |
ORBIMED ADVISORS LLC | 7,404,869 12.000% |
-629,131 (-7.83%) |
Filing History |
| 2024-11-14 7:24 pm Sale |
2024-09-30 | 13G | Scholar Rock Holding Corporation SRRK |
ORBIMED ADVISORS LLC | 503,400 0.600% |
-2,456,600 (-82.99%) |
Filing History |